Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • AstraZeneca, Max Planck Society deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Max Planck Society, Munich, Germany Business: Cardiovascular, Chemistry, Endocrine/Metabolic The societys Max Planck Institute of Molecular Physiology partnered with …

    Published on 7/28/2014
  • Bayer, University of Oxford deal

    Bayer AG (Xetra:BAYN), Leverkusen, Germany University of Oxford, Oxford, U.K. Business: Genitourinary Bayers Bayer HealthCare AG subsidiary partnered with the university to discover and develop therapies to treat …

    Published on 7/28/2014
  • Bio-Techne, Novus Biologicals deal

    Bio-Techne (NASDAQ:TECH), Minneapolis, Minn. Novus Biologicals LLC, Littleton, Colo. Business: Supply/Service, Antibodies Research tool supplier Bio-Techne acquired Novus for $60 million in cash. Novus supplies …

    Published on 7/28/2014
  • BioInvent, Servier deal

    BioInvent International AB (SSE:BINV), Lund, Sweden Servier, Neuilly-sur-Seine, France Business: Cancer, Antibodies BioInvent received an undisclosed milestone payment from Servier under a 2012 deal under which the …

    Published on 7/28/2014
  • Bristol-Myers, Ono Pharmaceutical deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Business: Cancer Bristol-Myers Squibb and Ono partnered to jointly develop and commercialize multiple products, …

    Published on 7/28/2014
  • C2N Diagnostics, Washington University in St. Louis deal

    C2N Diagnostics LLC, St. Louis, Mo. Washington University in St. Louis, St. Louis, Mo. Business: Neurology, Diagnostic The universitys school of medicine granted C2N Diagnostics exclusive, worldwide rights to …

    Published on 7/28/2014
  • Corgenix Medical Corp., Mellitus deal

    Corgenix Medical Corp. (OTCBB:CONX), Broomfield, Colo. Mellitus LLC, Cambridge, Mass. Business: Diagnostic Corgenix will develop a research test kit to measure glycated CD59 for use in Mellitus in vitro diagnostic for …

    Published on 7/28/2014
  • Epirus, AnaBios deal

    Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS), Boston, Mass. AnaBios Corp., San Diego, Calif. Business: Neurology Epirus (formerly Zalicus Inc.) granted CRO AnaBios exclusive, worldwide rights to develop and …

    Published on 7/28/2014
  • GlaxoSmithKline, Codexis deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Codexis Inc. (NASDAQ:CDXS), Redwood City, Calif. Business: Supply/Service Codexis granted GlaxoSmithKline a non-exclusive, worldwide license to use Codexis …

    Published on 7/28/2014
  • HD Biosciences, Marshall University deal

    HD Biosciences Co. Ltd., Shanghai, China Marshall University, Huntington, W.Va. Business: Cancer CRO HD Biosciences and the universitys Marshall Institute for Interdisciplinary Research (MIIR) and Joan C. Edwards School…

    Published on 7/28/2014
  • Histogen, Wylde deal

    Histogen Inc., San Diego, Calif. Wylde LLC, Calif. Business: Cancer, Gene/Cell therapy The companies formed a JV, Histogen Oncology, to develop cell-derived materials to treat cancer. Histogen Oncology has exclusive, …

    Published on 7/28/2014
  • Merz, Brickell Biotech deal

    Merz GmbH & Co. KGaA, Frankfurt, Germany Brickell Biotech Inc., Miami, Fla. Business: Autoimmune, Dermatology Merzs Merz North America Inc. received exclusive, North American rights plus undisclosed, international …

    Published on 7/28/2014
  • Monsanto, Tekmira deal

    Monsanto Co. (NYSE:MON), St. Louis, Mo. Tekmira Pharmaceuticals Corp. (TSX:TKM;NASDAQ:TKMR), Burnaby, B.C. Business: Agbio/Environmental Tekmira received a $1.5 million milestone payment from Monsanto under a January …

    Published on 7/28/2014
  • Nicox, Rapid Pathogen Screening deal

    Nicox S.A. (Euronext:COX), Sophia Antipolis, France Rapid Pathogen Screening Inc., Sarasota, Fla. Business: Diagnostic Nicox restructured a 2012 deal with Rapid Pathogen Screening (RPS) granting Nicox exclusive, …

    Published on 7/28/2014
  • Ono Pharmaceutical, University of Tokyo deal

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan University of Tokyo, Tokyo, Japan Business: Pharmaceuticals Ono will provide the universitys Open Innovation Center for Drug Discovery access to the pharmas …

    Published on 7/28/2014
  • Pfizer, The Epilepsy Foundation, Intellimedix deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. The Epilepsy Foundation, Landover, Md. Intellimedix Inc., Atlanta, Ga. Business: Neurology The Epilepsy Foundation partnered with Intellimedix and Pfizer to develop drug discovery …

    Published on 7/28/2014
  • PharmaMar, GP Pharm deal

    PharmaMar S.A., Madrid, Spain GP Pharm S.A., Barcelona, Spain Business: Cancer PharmaMars PharmaMar s.r.l. subsidiary received exclusive rights to market GP Pharms Politrate leuprorelin in Italy. The product, which is …

    Published on 7/28/2014
  • Portola, Daiichi Sankyo deal

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cardiovascular Daiichi partnered with Portola to conduct Phase III trials to evaluate …

    Published on 7/28/2014
  • Rohto, International Stem Cell deal

    Rohto Pharmaceutical Co. Ltd. (Tokyo:4527), Osaka, Japan International Stem Cell Corp. (OTCBB:ISCO), Carlsbad, Calif. Business: Gene/Cell therapy Rohto will evaluate human cells derived from International Stem Cells …

    Published on 7/28/2014
  • Shanghai Fosun Pharmaceutical, miacom diagnostics deal

    Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196;HKSE:2196), Shanghai, China miacom diagnostics GmbH, Duesseldorf, Germany Business: Diagnostic Shanghai Fosuns Fosun Diagnostics division received exclusive,…

    Published on 7/28/2014
  • Shire, ArmaGen deal

    Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland ArmaGen Technologies Inc., Calabasas, Calif. Business: Endocrine/Metabolic ArmaGen granted Shire exclusive, worldwide rights to develop and commercialize AGT-182, which …

    Published on 7/28/2014
  • Teva, Labrys Biologics deal

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Labrys Biologics Inc., San Mateo, Calif. Business: Neurology Teva completed its acquisition of Labrys for $200 million in cash up front plus up to $…

    Published on 7/28/2014
  • Ventrus Biosciences, Assembly deal

    Ventrus Biosciences Inc., New York, N.Y. Assembly Pharmaceuticals Inc., San Francisco, Calif. Business: Infectious The companies completed their merger in a stock deal. Assembly shareholders received 20 million Ventrus …

    Published on 7/28/2014
  • Abbott, Mylan deal

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Generics Mylan will acquire Abbotts ex-U.S. developed markets branded generics business in a stock deal. Abbott will …

    Published on 7/21/2014
  • Agency for Science, Technology and Research, ImmunID deal

    Agency for Science, Technology and Research, Singapore ImmunID S.A.S., Grenoble, France Business: Autoimmune ImmunID partnered with the agency (A*STAR) to use ImmunIDs ImmunTraCkeR and ImmunIG tests to evaluate T and B …

    Published on 7/21/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993